Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

third quarter of 2007 were $1.0 million compared to $2.2 million for the same period in the prior year. Restructuring charges in 2007 relate primarily to initiatives to restructure operations announced in March 2007 while restructuring charges in 2006 related to initiatives to restructure operations announced in June 2006.

In the third quarter of 2007, NPS sold its rights to the PREOTACT royalty to Drug Royalty Corporation for $50 million up-front with an additional $25 million to be paid upon the achievement of certain revenue milestones. Although the sale is non recourse, under U.S. generally accepted accounting pronouncements this transaction will be treated as debt. NPS also issued $100 million of non recourse Sensipar backed B bonds, and issued $50 million of new 5.75% convertible debt due 2014. In the third quarter, NPS repurchased $20.2 million of 3% Convertible Notes due 2008 for $19.5 million.

As of September 30, 2007, the company had 46.4 million shares outstanding and $302.2 million in cash, cash equivalents and marketable investment securities as compared to $146.2 million at December 31, 2006.

NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2007 2006 2007 2006

Revenues $29,161 $10,071 $52,267 $24,436

Operating expenses

Cost of goods sold 823 536 2,875 902

Cost of royalties 1,228 796 3,363 1,954

Research and

development 5,400 13,692 28,121 55,076

Selling, general

and administrative 5
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... Calif. , Feb. 26, 2015  23andMe, the ... Kate Black as Privacy Officer and Corporate ... and state privacy laws as well as health care ... team, she will be responsible for reviewing, updating and ... in the U.S. and abroad. She joined the company ...
(Date:2/26/2015)... JOLLA, Calif. , Feb. 26, 2015   ... a biopharmaceutical company leading the discovery and development of ... G. Xanthopoulos , Ph.D., President and Chief Executive Officer ... Cowen and Company 35 th Annual Healthcare Conference ... The conference is being held at the Boston Marriott ...
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... , Feb. 26, 2015 The healthcare landscape ... ever-changing arena, Frost & Sullivan will host its 20 ... Executive MindXchange , March 8 to 10, at the Hilton ... Calif. This event is a platform ... leaders to discuss industry disruptions and how to succeed in ...
Breaking Biology Technology:23andMe Appoints Kate Black as Privacy Officer and Corporate Counsel 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 2Regulus to Present at Cowen and Company 35th Annual Healthcare Conference 3Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Embrace the Future of Medical Technologies with Frost & Sullivan 2Embrace the Future of Medical Technologies with Frost & Sullivan 3
... US - A team of Bioengineers in the United ... its ability to produce ethanol. The research, published in ... metabolic engineering can be combined for strain improvement, a ... focused their research on Zymomonas mobilis, a bacterium noted ...
... NEW YORK, Dec. 10, 2010 Ramius V&O Acquisition ... announced that it has sent a letter to the ... CYPB ) outlining its willingness to acquire all ... for $5.50 per share.  The offer is conditioned upon ...
... new hand-held medical device will help UK athletes reach ... sporting competitions. UK Sport, the UK,s high performance sports ... organisation to use cutting edge technology developed by Argento ... athletes will be able to monitor various proteins which ...
Cached Biology Technology:Bioengineers develop bacterial strain to increase ethanol biofuel production 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 2Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 3Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 4Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 5Ramius Offers to Enter Into Immediate and Exclusive Negotiations to Acquire Cypress Bioscience for $5.50 Per Share 6Medical science helps UK athletes reach peak performance 2Medical science helps UK athletes reach peak performance 3
(Date:2/11/2015)... 2015 According to ... Market by Product (Cards and Readers, Biometrics, Controllers, Management ... Industrial, Healthcare, Education) and By Geography - Global Forecast and Analysis ... Access Control Market is expected to reach ... CAGR of 10.6% between 2014 and 2020. ...
(Date:2/5/2015)... , Feb. 5, 2015  Marken is starting ... company and has launched a new marketing campaign to ... Organization (CLO).  The new campaign focuses on First ... protocol and shipments. The first headline in ... aligns Marken,s priorities with its client,s priorities. Marken recognizes ...
(Date:2/5/2015)... 2015 New Market Research Reports ... Forecasts To 2020 has Been Added to GrandViewReseach.com Report ... expected to reach USD 5.10 billion by 2020, according ... IR cameras help identify the site of tissue damage ... surging demand in medical imaging applications. They have been ...
Breaking Biology News(10 mins):Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4Marken Launches New Patient-Centric Campaign 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3
... an experimental vaccine targeting West Nile virus (WNV) opened ... Center in Bethesda, MD. The vaccine, which will be ... for human clinical studies by researchers at the National ... Center (VRC), and Vical Inc., San Diego, based on ...
... the vertebrate embryo - the establishment of a back ... - turns out to be so important that the ... it happens properly. , The discovery, reported this month ... University of California, Berkeley, finally explains an 80-year-old observation ...
... recently discovered a gene essential to one of the ... use PCD to create a protective zone of dead ... pathogen from spreading. But how the plants keep from ... was a mystery. , Now, in the May 20 ...
Cached Biology News:NIAID begins clinical trial of West Nile virus vaccine 2NIAID begins clinical trial of West Nile virus vaccine 3Scientists discover that three overlapping signals in embryo help get the backbone right 2Scientists discover that three overlapping signals in embryo help get the backbone right 3Scientists discover that three overlapping signals in embryo help get the backbone right 4Scientists discover that three overlapping signals in embryo help get the backbone right 5Plant Sacrifices Cells to Fight Invaders 2
... X-Gal ,MOLECULAR BIOLOGY GRADE ,5-Bromo-4-chloro-3-indoxyl-beta-D-galactopyranoside ... Br Cl N O 6 ... (HPLC) ,Solution: Clear (2% in DMF) ... pUC and M13 ,Elemental Analysis: Agrees ...
...
Antibodies were affinity purified using epitopes specific to RFC1 immobilized on solid support....
prototype Nco I...
Biology Products: